达拉非尼诱导的嗜中性脂膜炎，发生在一名接受双重BRAF-MEK抑制剂治疗多形性胶质母细胞瘤的儿童身上。
Dabrafenib-induced neutrophilic panniculitis in a child undergoing dual BRAF-MEK inhibitor therapy for glioblastoma multiforme.
作者信息
Young Trevor K, Gutierrez Daniel, Criscito Maressa C, Kim Randie H, Lakdawala Nikita, Oza Vikash S
机构信息
The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York, USA.
出版信息
Pediatr Dermatol. 2020 Nov;37(6):1185-1186. doi: 10.1111/pde.14306. Epub 2020 Sep 1.
BRAF inhibitor-induced neutrophilic panniculitis is a rare event that is well-characterized in adults undergoing therapy for metastatic melanoma. To date, there are very few reports of this event in children undergoing BRAF inhibitor therapy for low-grade gliomas, all of which were seen with vemurafenib. We report a case of dabrafenib-induced neutrophilic panniculitis in a 9-year-old girl that manifested within several weeks of initiating dual BRAF-MEK inhibitor therapy for glioblastoma multiforme. This case highlights neutrophilic panniculitis as a side effect of dabrafenib in children and serves as a reminder to consider cutaneous side effects of BRAF inhibitors as they are increasingly used to treat children with primary brain tumors.
BRAF抑制剂诱发的嗜中性脂膜炎是一种罕见事件，在接受转移性黑色素瘤治疗的成人中已有充分描述。迄今为止，在接受BRAF抑制剂治疗低级别胶质瘤的儿童中，关于这一事件的报道极少，且所有报道均与维莫非尼有关。我们报告了一例9岁女孩因达拉非尼诱发嗜中性脂膜炎的病例，该病例在开始针对多形性胶质母细胞瘤的BRAF-MEK双靶点抑制剂治疗后的几周内出现。该病例凸显了嗜中性脂膜炎作为达拉非尼在儿童中的一种副作用，同时也提醒人们，随着BRAF抑制剂越来越多地用于治疗儿童原发性脑肿瘤，应考虑其皮肤副作用。
Zotero 插件